Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Tempus Al Inc. maintains a portfolio with 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners and 4 distinct art units. NEGIN, RUSSELL SCOTT is the busiest examiner for the company, currently managing 2 pending office actions. The presence of 4 distinct art units indicates that the company's intellectual property covers several different technical classifications within the biotechnology sector.
With 6 distinct examiners reviewing 7 pending office actions, the company must manage multiple simultaneous examiner interactions. The fact that NEGIN, RUSSELL SCOTT is the busiest examiner with 2 pending office actions suggests a relatively even distribution of the workload across the rest of the 6 distinct examiners. This diversity in examiners and art units may require the company to adapt its prosecution strategy to various individual examiner styles and art unit standards. The concentration of 7 pending office actions within 4 distinct art units shows that while the examiners vary, the technical subject matter is somewhat more clustered. This structure requires a balance between specialized technical arguments for each of the 4 art units and individualized communication with the 6 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (71%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEGIN, RUSSELL SCOTT | 2 | 55.9% | +34.2% |
| HRANEK, KAREN AMANDA | 1 | 34.5% | +39.9% |
| NGUYEN, TRI T | 1 | 67.3% | +15.8% |
| NGUYEN, PETER | 1 | — | — |
| ANDERSON-FEARS, KEENAN NEIL | 1 | 12.0% | +41.3% |
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18513153 | METHOD AND PROCESS FOR PREDICTING AND ANALYZING PATIENT COHORT RESPONSE, PROGRESSION, AND SURVIVAL | HRANEK, KAREN AMANDA | — |
| 18478889 | METHODS AND SYSTEMS FOR DISEASE PHENOTYPING USING MULTIMODAL EHR DATA AND WEAK SUPERVISION | NGUYEN, TRI T | — |
| 18261985 | METHODS AND SYSTEMS FOR mRNA BOUNDARY ANALYSIS IN NEXT GENERATION SEQUENCING | NGUYEN, PETER | — |
| 17800492 | SYSTEMS AND METHODS FOR DETECTING VIRAL DNA FROM SEQUENCING | NEGIN, RUSSELL SCOTT | — |
| 17527657 | METHODS AND SYSTEMS FOR REFINING COPY NUMBER VARIATION IN A LIQUID BIOPSY ASSAY | ANDERSON-FEARS, KEENAN NEIL | — |
| 17323982 | SYSTEMS AND METHODS FOR USING SEQUENCING DATA FOR PATHOGEN DETECTION | NEGIN, RUSSELL SCOTT | — |
| 16945588 | METHODS AND SYSTEMS FOR DETECTING MICROSATELLITE INSTABILITY OF A CANCER IN A LIQUID BIOPSY ASSAY | BAILEY, STEVEN WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18513153 | METHOD AND PROCESS FOR PREDICTING AND ANALYZING PATIENT COHORT RESPONSE, PROGRESSION, AND SURVIVAL | HRANEK, KAREN AMANDA | — |
| 18478889 | METHODS AND SYSTEMS FOR DISEASE PHENOTYPING USING MULTIMODAL EHR DATA AND WEAK SUPERVISION | NGUYEN, TRI T | — |
| 17800492 | SYSTEMS AND METHODS FOR DETECTING VIRAL DNA FROM SEQUENCING | NEGIN, RUSSELL SCOTT | — |
| 17527657 | METHODS AND SYSTEMS FOR REFINING COPY NUMBER VARIATION IN A LIQUID BIOPSY ASSAY | ANDERSON-FEARS, KEENAN NEIL | — |
| 17323982 | SYSTEMS AND METHODS FOR USING SEQUENCING DATA FOR PATHOGEN DETECTION | NEGIN, RUSSELL SCOTT | — |
| 16945588 | METHODS AND SYSTEMS FOR DETECTING MICROSATELLITE INSTABILITY OF A CANCER IN A LIQUID BIOPSY ASSAY | BAILEY, STEVEN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 1687 | 2 |
| 3684 | 1 |
| 2128 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18513153 | METHOD AND PROCESS FOR PREDICTING AND ANALYZING PATIENT COHORT RESPONSE, PROGRESSION, AND SURVIVAL | HRANEK, KAREN AMANDA | 3684 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18478889 | METHODS AND SYSTEMS FOR DISEASE PHENOTYPING USING MULTIMODAL EHR DATA AND WEAK SUPERVISION | NGUYEN, TRI T | 2128 | §101§103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18261985 | METHODS AND SYSTEMS FOR mRNA BOUNDARY ANALYSIS IN NEXT GENERATION SEQUENCING | NGUYEN, PETER | — | §101§102§103 | Non-Final OA | — | Pending | Jul 18, 2023 |
| 17800492 | SYSTEMS AND METHODS FOR DETECTING VIRAL DNA FROM SEQUENCING | NEGIN, RUSSELL SCOTT | 1686 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17527657 | METHODS AND SYSTEMS FOR REFINING COPY NUMBER VARIATION IN A LIQUID BIOPSY ASSAY | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101DP | Final Rejection | — | Pending | Nov 16, 2021 |
| 17323982 | SYSTEMS AND METHODS FOR USING SEQUENCING DATA FOR PATHOGEN DETECTION | NEGIN, RUSSELL SCOTT | 1686 | §103§112 | Final Rejection | — | Pending | May 18, 2021 |
| 16945588 | METHODS AND SYSTEMS FOR DETECTING MICROSATELLITE INSTABILITY OF A CANCER IN A LIQUID BIOPSY ASSAY | BAILEY, STEVEN WILLIAM | 1687 | §101§112 | Final Rejection | — | Pending | Jul 31, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial